超声引导下放射性粒子植入治疗肝细胞癌患者短期疗效研究*

doi:10.3969/j.issn.1672-5069.2022.02.028

Abstract

Abstract: Objective The aim of this study was to investigate the influencing factors of disease control after ultrasound-guided 125I radioactive seed implantation for patients with hepatocellular carcinoma (HCC). Methods 84 patients with HCC were admitted to our hospital betweenJuly 2017 and August 2021, and all patients received ultrasound-guided intrahepatic 125I radioactive seed implantation with particle activity of 0.6-0.8 mCi and the tumor matched peripheral dose (MPD) of 110-160 Gy. The CT or MRI scan was performed 2 months after the operation and the short-term efficacy was evaluated according to RECIST standard version 1.1. The multivariate Logistic regression analysis was applied to screen for independent factors impacting disease control (the sum of complete response, partial response and disease stable). Results The intratumorous implantation of radioactive125I seeds was successfully finished in our 84 patients with HCC; at the end of two months after surgery, the imaging showed disease control in 69 cases (82.1%), including complete remission in 15 cases (17.9%), partial remission in 47 cases (56.0%) and disease stable in 7 cases (8.3%), with disease progression in 15 cases (17.9%); the univariate Logistic regression analysis showed that the proportions of Child-Pugh class B, BCLC stage C, tumor diameter > 5 cm and the received irradiation dose of 90% target volume (D90 dose) < 110 Gy in thedisease control group were 40.0%, 43.5%, 40.9% and 28.6%, all significantly lower than 60.0%, 56.5%, 59.1% and 71.4% in the disease progression group (P<0.05); the multivariate Logistic regression analysis showed that the D90 dose was an independent factor impacting disease control in patients with HCC after ultrasound-guided radioactive125I seed implantation (OR=344.350, P<0.05). Conclusion The sufficient irradiation dose is necessary in patients with unresectable HCC receiving intratumorous radioactive125I seed implantation in order to gain therapeutic efficacy, which needs further clinical investigation.

Key words: Hepatoma, Ultrasound-guidance, 125I radioactive particles, Disease control

Wang Xinran, Jiang Yandong, Zhang Meng. Local control of tumors in patients with hepatocellular carcinoma receiving ultrasound-guided intratumorous125I radioactive particle implantation[J]. Journal of Practical Hepatology, 2022, 25(2): 263-266.

References

[1] Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: new trends. J Hepatol, 2020, 72(2):250-261.
[2] Nakada S, Allard MA, Lewin M, et al. Ischemic cholangiopathy following transcatheter arterial chemoembolization for recurrent hepatocellular carcinoma after hepatectomy: an underestimated and devastating complication. J Gastrointest Surg, 2020, 24(11):2517-2525.
[3] Park GC, Lee SG, Yoon YI, et al. Sequential transcatheter arterial chemoembolization and portal vein embolization before right hemihepatectomy in patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int, 2020, 19(3):244-251.
[4] Li S, He X, Dang L, et al. Efficacy of125 I versus non- 125 I combined with transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma with obstructive jaundice. Dig Dis Sci, 2018, 63(2):321-328.
[5] 刘红艳, 王坤远, 樊蓉, 等. 十年磨一剑:肝细胞癌诊疗新进展. 中华肝脏病杂志, 2021, 29(2):111-115.
[6] He C, Liu Y, Li Y, et al. Efficacy and safety of computed tomography-guided125 I brachytherapy for lymph node metastatic from hepatocellular carcinoma. J Cancer Res Ther, 2018, 14(4):754-759.
[7] 中华人民共和国卫生和计划生育委员会医政医管局. 原发性肝癌诊疗规范(2017年版). 中华消化外科杂志, 2017, 16(7):635-647.
[8] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 2009, 45(2):228-247.
[9] Wang X, Hu X, Liu X, et al. The efficacy of99m Tc-MIBI imaging in 125 I seed implantation treatment of rabbit VX2 transplanted liver cancer. Int J Clin Exp Pathol, 2019, 12(6):2363-2367.
[10] Li CG, Zhou ZP, Jia YZ, et al. Radioactive125 I seed implantation for pancreatic cancer with unexpected liver metastasis: a preliminary experience with 26 patients. World J Clin Cases, 2021, 9(4):792-800.
[11] Fan T, Zhou JY. Computed tomography-guided125I radioactive seed implantation therapy for pancreatic cancer pain. J Coll Physicians Surg Pak, 2020, 30(4):364-368.
[12] Li D, Wang WJ, Wang YZ, et al. Lobaplatin promotes125 I-induced apoptosis and inhibition of proliferation in hepatocellular carcinoma by upregulating PERK-eIF2α-ATF4-CHOP pathway. Cell Death Dis, 2019, 10(10):744-753.
[13] Zeng Y, Mao Y, Shi Z, et al. Observation of therapeutic effect of125I seed implantation combined with chemotherapy and antiviral therapy on HBV-related liver cancer. J BUON, 2019, 24(4):1414-1419.
[14] Zhang H, Yang A, Zhang J. Efficacy of transcatheter arterial chemoembolization combined with125I seed implantation and three-dimensional conformal radiotherapy in advanced primary hepatocellular carcinoma. J BUON, 2020, 25(2):952-958.
[15] Yuan D, Gao Z, Zhao J, et al.125 I seed implantation for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis. Brachytherapy, 2019, 18(4):521-529.
[16] Guo Y, Li T, Yan J. Letter to the editor regarding "125I seed implantation for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and metaanalysis". Brachytherapy, 2021, 20(2):494-495.
[17] Li J, Zhang L, Sun Z, et al. Iodine-125 seed implantation for residual hepatocellular carcinoma or cholangiocellular carcinoma in challenging locations after transcatheter arterial chemoembolization: Initial experience and findings. J Contemp Brachytherapy, 2020, 12(3):233-240.
[18] 陈恩立, 张宏涛, 刘泽洲, 等. CT引导125I粒子植入治疗头颈部复发转移肿瘤近期疗效的影响因素分析. 中华核医学与分子影像杂志, 2020, 40(2):93-97.
[19] 曲昂, 孙海涛, 姜伟娟, 等. 剂量学参数对CT引导125I放射性粒子植入治疗放疗后盆腔复发宫颈癌疗效的影响. 中华医学杂志, 2018, 98(37):3014-3016.
[20] 吉喆, 霍彬, 邢超, 等.125I粒子植入治疗早期非小细胞肺癌的临床效果和预后分析. 中华放射医学与防护杂志, 2021, 41(1):31-36.

Local control of tumors in patients with hepatocellular carcinoma receiving ultrasound-guided intratumorous125I radioactive particle implantation

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Liu Huimin, Liu Xiaoli, Wang Xinhui, et al. Implication of peripheral CD4+T, CD8+T, Tc17, Th17 and Treg lymphocyte changes in patients with primary liver cancer [J]. Journal of Practical Hepatology, 2022, 25(2): 255-258.
[2]	Wang Chan, Shen Changqing, Wu Xiaoqiong, et al. Efficacy and safety of epirubicin drug-eluting beads-transcatheter arterial chemoembolization in the treatment of patients with unresectable primary liver cancer [J]. Journal of Practical Hepatology, 2022, 25(2): 259-262.
[3]	Wang Lianshuang, Zhang Yao, Shan Tao, et al. Ultrasonographic feature and prognosis of patients with hepatocellular carcinaoma and cardiac metastases: Analysis of 19 cases [J]. Journal of Practical Hepatology, 2022, 25(2): 271-274.
[4]	Li Huan, Li Yang, Du Juan, et al. Cancerous expression and functional relations of glypican3 and sonic Hedgehog proteins in patients with hepatocellular carcinoma and in hepatoma cell lines in vitro [J]. Journal of Practical Hepatology, 2022, 25(1): 83-87.
[5]	Peng Nan, Ma Aizhen, Shi Zhan, et al. Application of CT 3D reconstruction in the evaluation of resectability of massive intrahepatic tumors in patients with primary liver cancer [J]. Journal of Practical Hepatology, 2022, 25(1): 96-99.
[6]	Zhou Yan, Li Guoping, Deng Jun, et al. Efficacy of thymosin alpha 1 in maintained treatment of patients with primary liver cancer after radiofrequency ablation [J]. Journal of Practical Hepatology, 2021, 24(6): 907-910.
[7]	Zhou Zheng, Liu Wei. Contrast-enhanced ultrasound features of hepatic hemangioma, hepatocellular carcinoma and hepatic angiomyolipoma [J]. Journal of Practical Hepatology, 2021, 24(6): 911-914.
[8]	Zhao Pengfei, Zu Hongmei, Xin Xiaoen, et al. Logistic regression analysis of risk factors in patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2021, 24(6): 927-929.
[9]	Peng Guangming, Ge Shang, Jin Guiyin. Image quality of adaptive statistical iterative reconstruction under low tube voltage of CT scan in diagnosis of patients with primary liver cancer [J]. Journal of Practical Hepatology, 2021, 24(5): 737-740.
[10]	Yu Lei, Sun Chao, Zhang Manxu. Regulation of intestinal floras and their metabolism functions by ganoderma lucidum plysaceharide in mice with HepG2 cell-induced implanted cancer [J]. Journal of Practical Hepatology, 2021, 24(4): 476-479.
[11]	Chen Wei, Wei Tao, Yang Lan, et al. Expression of NLRP3 inflammasome in cancerous tissues of patients with primary liver cancer [J]. Journal of Practical Hepatology, 2021, 24(4): 544-547.
[12]	Liu Yongchang, Zhao Diantang, Sun Qifeng, et al. Application of indocyanine green fluorescence navigationand three-dimensional visualization in laparoscopic precision surgery for patients with primary liver cancer [J]. Journal of Practical Hepatology, 2021, 24(4): 561-564.
[13]	Gao Jinlong, Wang Haifeng, Li Na, et al. Target delineation accuracy of tumors for radiotherapy based on MR-T2 image in patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2021, 24(4): 565-568.
[14]	Wang Qunxian, Wang Yunchuan, Chen Youying. Effect of sevoflurane inhalation at different times during anesthesia in patients with primary liver cancer undergoing partial hepatectomy [J]. Journal of Practical Hepatology, 2021, 24(4): 597-599.
[15]	An Xiquan, Li Yan, Menggen Caicike. Clinical observation of tenofovir and sorafenib in the treatment of patients with hepatitis B associated advanced primary liver cancer [J]. Journal of Practical Hepatology, 2021, 24(4): 600-602.